Clinical Performance of a Lateral Flow SARS-CoV-2 Total Antibody Assay
- PMID: 35296885
- PMCID: PMC8992344
- DOI: 10.1093/jalm/jfac003
Clinical Performance of a Lateral Flow SARS-CoV-2 Total Antibody Assay
Abstract
Background: Serological assays for SARS-CoV-2 are important tools for diagnosis in patients with negative RT-PCR testing, pediatric patients with multisystem inflammatory syndrome, and serosurveillance studies. However, lateral flow-based serological assays have previously demonstrated poor analytical and clinical performance, limiting their utility.
Methods: We assessed the ADEXUSDx COVID-19 lateral flow assay for agreement with diagnostic RT-PCR testing using 120 specimens from RT-PCR-positive patients, 77 specimens from symptomatic RT-PCR-negative patients, and 47 specimens obtained prepandemic. Specimens collected <14 days from symptom onset in RT-PCR-positive patients were compared relative to the Abbott SARS-CoV-2 IgG assay.
Results: The ADEXUSDx COVID-19 Test yielded an overall positive percent agreement (PPA) of 92.5% (95%CI 85.8 to 96.3) and negative percent agreement of 99.2% (95% CI 94.9-100.0) relative to RT-PCR and in prepandemic specimens. Relative to days from symptom onset, the PPA after 13 days was 100% (95% CI 94.2-100); from 7 to 13 days, 89.7 (95% CI 71.5-97.2); and from 0 to 7 days, 53.8 (95% CI 26.1-79.6). The overall agreement between the Abbott and ADEXUSDx assays was 80.9%. Twenty-five specimens were positive by both assays, 9 specimens were negative by both assays, and 8 specimens were positive by only the ADEXUSDx assay.
Conclusions: We demonstrate high PPA and negative percent agreement of the ADEXUSDx COVID-19 assay and diagnostic testing by RT-PCR, with PPA approximately 90% by 7 days following symptom onset. The use of waived testing for antibodies to SARS-CoV-2 with high sensitivity and specificity provide a further tool for combatting the COVID-19 pandemic.
Keywords: COVID-19; SARS-CoV-2; antibody; immunity; serology.
© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
References
-
- Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Published April 11, 2020. Last updated January 18, 2022. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatmen... (Accessed January 2021).
-
- Infectious Diseases Society of America. IDSA guidelines on the diagnosis of COVID-19: serologic testing. Published August 18, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-serology (Accessed August 2021).
-
- Food and Drug Administration. In vitro diagnostics EUAs—serology and other adaptive immune response tests for SARS-CoV-2. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em... (Accessed August 2021).
-
- Clinical & Laboratory Standards Institute. Overcoming phlebotomy challenges in pediatric patients. Published July 15, 2020. https://clsi.org/about/blog/overcoming-phlebotomy-challenges-in-pediatri... (Accessed August 2021).
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
